Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Centratama Telekomunikasi Indonesia Tbk. (CENT) vs Dharma Polimetal Tbk. (DRMA) Price & Performance

Centratama Telekomunikasi Indonesia Tbk.Trade
Dharma Polimetal Tbk.Trade

Price performance (Past 24H)

Key statistics

Centratama Telekomunikasi Indonesia Tbk. vs Dharma Polimetal Tbk. — how do they compare? Centratama Telekomunikasi Indonesia Tbk. trades at Rp83 (market cap 2.59T, 2.3M 24h volume), while Dharma Polimetal Tbk. trades at Rp985 (market cap 4.64T, 531.1K 24h volume). The key difference: Dharma Polimetal Tbk. is the larger of the two by market cap, and Centratama Telekomunikasi Indonesia Tbk. is more actively traded (2.3M versus 531.1K). Which is the better fit depends on your goals.

CENTDRMA
Market Cap
2.59T4.64T
Volume
2.3M531.1K
Lot
22.99K5.31K
Turnover
190.59M523.32M
Average Price
82.9985.35
Value
190.59M523.32M
Indicative Equilibrium Price
83985
Indicative Equilibrium Volume
201125

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

CENT
View details
DRMA
View details

About Centratama Telekomunikasi Indonesia Tbk.

PT Centratama Telekomunikasi Indonesia Tbk formerly Centrin Online The corporate was established on February 11th 1987 in Bandung as PT. Centrindo Utama. Since the first establishment, corporate focus the business on the information technology. Start the operation in computer hardware sales such as supporting hardware and monitor which produced by PT. Central Rama Informatiko as a affiliated company. And start the internet service provider business on 1996.

Read more on CENT

About Dharma Polimetal Tbk.

PT Dharma Polimetal Tbk (“the Company”) was established in the Republic of Indonesia on 27 March based on Notarial deed No. 74 of Rukmasanti Hardjasatya, S.H. The Company begin opertions on year 1989 and commenced its commercial activities since 1990. The Company’s Majority shareholder is PT Dharma Inti Anugerah, established in Republic Indonesia on 20 November 2003.

Read more on DRMA